Abrocitinib

(Cibinqo®)

Abrocitinib

Drug updated on 11/15/2023

Dosage FormTablet (oral: 50 mg, 100 mg, 200 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

Product Monograph / Prescribing Information

Document TitleYearSource
Cibinqo (abrocitinib) Prescribing Information.2022Pfizer Labs, New York, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Clinical and pharmacoeconomic combined report.2023CADTH
Oral Janus kinase inhibitors in the treatment of atopic dermatitis: a systematic review and meta‐analysis.2023Skin Health and Disease
Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.2023Heliyon
Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. 2023British Journal of Dermatology
Systemic treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. 2023The Journal of Allergy and Clinical Immunology
The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. 2023Journal of the European Academy of Dermatology & Venerelogy
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis. 2022NICE
Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: a network meta‐analysis. 2022Dermatologic Therapy
Comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis without topical corticosteroids: systematic review and network meta-analysis.2022Dermatology and Therapy
Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis.2022JAMA Dermatology
Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials.2022Journal of Demagogical Treatment
Efficacy of biologics and oral small molecules for atopic dermatitis: a systematic review and meta-analysis.2022Journal of Demagogical Treatment
Assessment report: Cibinqo.2021EMA
JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value.2021ICER
Effectiveness and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a systematic review and meta-analysis of randomized clinical trials.2021Dermatology Research and Practice
Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.2021Journal of the European Academy of Dermatology and Venereology
Systematic review on the efficacy and safety of oral Janus kinase inhibitors for the treatment of atopic dermatitis.2021Frontiers in Medicine
Short-term effectiveness and safety of biologics and small molecule drugs for moderate to severe atopic dermatitis: a systematic review and network meta-analysis.2021Life
Efficacy and safety of Janus kinase inhibitors for the treatment of atopic dermatitis: a systematic review and meta-analysis.2021Dermatology
Comparing quality of life outcomes of JAK inhibitors and biological treatments for atopic dermatitis: a systematic review and network meta-analysis.2021Expert Review of Clinical Pharmacology